eli lilly retatrutide ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial Eli Lilly’s Phase 3 data

: European Journal of Nutrition

Digestive changes including constipation or diarrhea may occur as GLP-1 medications slow gastric emptying

As a synthetic growth hormone-releasing peptide, IGF-1 LR3 is renowned for its ability to promote anabolic muscle cell signaling and extend the half-life of growth factor analogs

The FDA is not bound to follow the committees advice, but it usually does

And they point the way to a new class of antidepressants that could be freer of side effects and faster-acting than those in use today, and that may help patients for whom existing treatments don't work or have stopped working

Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M